EC clears new class of anaemia therapy
BMS’ Reblozyl is the first and only erythroid maturation agent approved in the EU
Read More
Tag: Reblozyl
CHMP puts eight new medicines forward for approval
The recommendations bring closer to approval new therapies for asthma, acute myeloid leukaemia, transfusion-dependent anaemia, diabetes, prostate cancer, schizophrenia and multiple sclerosis
Read More
- Ipsen announces new data on Dysport in neurological disease
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
